DK1681353T3 - Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35 - Google Patents
Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35Info
- Publication number
- DK1681353T3 DK1681353T3 DK05077719T DK05077719T DK1681353T3 DK 1681353 T3 DK1681353 T3 DK 1681353T3 DK 05077719 T DK05077719 T DK 05077719T DK 05077719 T DK05077719 T DK 05077719T DK 1681353 T3 DK1681353 T3 DK 1681353T3
- Authority
- DK
- Denmark
- Prior art keywords
- adenovirus
- serotypes
- tropism
- proteins
- gene transfer
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 108090000565 Capsid Proteins Proteins 0.000 abstract 3
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 3
- 230000010415 tropism Effects 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 101710145505 Fiber protein Proteins 0.000 abstract 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99201545 | 1999-05-17 | ||
PCT/NL2000/000325 WO2000070071A1 (en) | 1999-05-17 | 2000-05-16 | Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1681353T3 true DK1681353T3 (da) | 2010-01-04 |
Family
ID=8240209
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05077719T DK1681353T3 (da) | 1999-05-17 | 2000-05-16 | Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35 |
DK00201738.2T DK1054064T4 (da) | 1999-05-17 | 2000-05-16 | Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35 |
DK07106044.6T DK1816204T3 (da) | 1999-05-17 | 2000-05-16 | Rekombinant adenovirus af Ad26-serotypen |
DK04077434T DK1550722T3 (da) | 1999-05-17 | 2000-05-16 | Rekombinant human adenovirus serotype 35 |
DK07106054.5T DK1816205T3 (da) | 1999-05-17 | 2000-05-16 | Rekombinant adenovirus på grundlag af serotypen Ad48 |
DK07106036.2T DK1818408T3 (da) | 1999-05-17 | 2000-05-16 | Rekombinant adenovirus af serotypen Ad11 |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00201738.2T DK1054064T4 (da) | 1999-05-17 | 2000-05-16 | Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35 |
DK07106044.6T DK1816204T3 (da) | 1999-05-17 | 2000-05-16 | Rekombinant adenovirus af Ad26-serotypen |
DK04077434T DK1550722T3 (da) | 1999-05-17 | 2000-05-16 | Rekombinant human adenovirus serotype 35 |
DK07106054.5T DK1816205T3 (da) | 1999-05-17 | 2000-05-16 | Rekombinant adenovirus på grundlag af serotypen Ad48 |
DK07106036.2T DK1818408T3 (da) | 1999-05-17 | 2000-05-16 | Rekombinant adenovirus af serotypen Ad11 |
Country Status (14)
Country | Link |
---|---|
EP (6) | EP1816205B1 (da) |
JP (2) | JP4843145B2 (da) |
KR (1) | KR100741247B1 (da) |
AT (6) | ATE364707T1 (da) |
AU (1) | AU777041B2 (da) |
CA (1) | CA2372655C (da) |
CY (4) | CY1106762T1 (da) |
DE (4) | DE60045138D1 (da) |
DK (6) | DK1681353T3 (da) |
ES (5) | ES2372824T3 (da) |
IL (3) | IL146479A0 (da) |
NZ (1) | NZ515582A (da) |
PT (5) | PT1816205E (da) |
WO (1) | WO2000070071A1 (da) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2333425T5 (es) | 1995-06-15 | 2012-08-28 | Crucell Holland B.V. | Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica |
US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
US6869936B1 (en) | 1999-03-04 | 2005-03-22 | Crucell Holland B.V. | Means and methods for fibroblast-like or macrophage-like cell transduction |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US7094398B1 (en) | 1999-06-01 | 2006-08-22 | University Of Washington | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
US6558948B1 (en) | 1999-11-23 | 2003-05-06 | Stefan Kochanek | Permanent amniocytic cell line, its production and use for the production of gene transfer vectors |
EP1191105A1 (en) * | 2000-09-25 | 2002-03-27 | Galapagos Genomics B.V. | Gene delivery vectors provided with a tissue tropism for T-lymphocytes |
AU2001263689B2 (en) | 2000-05-31 | 2007-03-22 | University Of Saskatchewan | Modified bovine adenovirus having altered tropism |
US20040033605A1 (en) * | 2000-09-20 | 2004-02-19 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells |
DE60138403D1 (de) | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten |
EP1195440A1 (en) * | 2000-10-06 | 2002-04-10 | Introgene B.V. | Gene delivery vectors for stem cells |
WO2002029073A2 (en) * | 2000-10-06 | 2002-04-11 | Crucell Holland B.V. | Gene delivery vectors for stem cells |
US7459153B2 (en) | 2001-01-04 | 2008-12-02 | Wadell Goeran | Viral vectors for gene therapy |
US7109029B2 (en) | 2001-02-23 | 2006-09-19 | Cell Genesys, Inc. | Vector constructs |
AU2003210661A1 (en) * | 2002-01-24 | 2003-09-02 | Novartis Ag | Fiber shaft modifications for efficient targeting |
ES2310247T3 (es) | 2002-04-25 | 2009-01-01 | Crucell Holland B.V. | Vectores adenovirales estables y metodos de propagacion de los mismos. |
SI1497438T1 (sl) * | 2002-04-25 | 2010-03-31 | Crucell Holland Bv | Sredstva in postopki za pripravo adenovirusnih vektorjev |
JP4237449B2 (ja) * | 2002-06-05 | 2009-03-11 | 国立医薬品食品衛生研究所長 | アデノウィルスベクター |
US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
EP1553983A2 (en) | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
SG156535A1 (en) | 2002-12-17 | 2009-11-26 | Crucell Holland Bv | Recombinant viral-based malaria vaccines |
CN1934253A (zh) * | 2003-07-18 | 2007-03-21 | 昂尼克斯药物公司 | 用于治疗疾病的b亚组腺病毒载体 |
AU2005214090B2 (en) | 2004-02-23 | 2008-09-11 | Crucell Holland B.V. | Virus purification methods |
JP2007532656A (ja) * | 2004-04-12 | 2007-11-15 | アメリカ合衆国 | アデノウイルスベクターを用いて免疫応答を誘導するための方法 |
ATE491799T1 (de) * | 2004-05-26 | 2011-01-15 | Bayer Schering Pharma Ag | Chimäre adenoviren zur verwendung in der krebsbehandlung |
CA2583843C (en) | 2004-10-13 | 2010-09-21 | Crucell Holland B.V. | Improved adenoviral vectors and uses thereof |
NZ555907A (en) | 2004-11-16 | 2009-12-24 | Aeras Global Tb Vaccine Found | Multivalent vaccines comprising recombinant viral vectors |
CN101155915B (zh) | 2005-04-11 | 2013-12-04 | 克鲁塞尔荷兰公司 | 利用超滤进行病毒纯化 |
WO2007010028A1 (en) | 2005-07-22 | 2007-01-25 | Crucell Holland B.V. | Cell line for producing coronaviruses |
WO2007104792A2 (en) * | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
ES2532015T3 (es) | 2008-11-03 | 2015-03-23 | Crucell Holland B.V. | Método para la producción de vectores adenovíricos |
SG178254A1 (en) | 2009-08-07 | 2012-03-29 | Transgene Sa | Composition for treating hbv infection |
US20120315696A1 (en) * | 2010-02-15 | 2012-12-13 | Alfred Luitjens | METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS |
WO2011098592A1 (en) | 2010-02-15 | 2011-08-18 | Crucell Holland B.V. | Method for the production of ad26 adenoviral vectors |
US8771709B2 (en) | 2010-09-20 | 2014-07-08 | Crucell Holland B.V. | Therapeutic vaccination against active Tuberculosis |
US9168292B2 (en) | 2010-09-27 | 2015-10-27 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
CN102260712B (zh) * | 2011-05-31 | 2013-10-02 | 北京锤特生物科技有限公司 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
CN104379733B (zh) | 2012-03-12 | 2016-01-20 | 克鲁塞尔荷兰公司 | 具改变末端的重组腺病毒群 |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
MY169352A (en) | 2012-03-22 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
US9476061B2 (en) | 2012-05-24 | 2016-10-25 | Janssen Vaccines & Prevention B.V. | Adenoviral vectors for transduction of vascular tissue |
JP6333814B2 (ja) | 2012-07-10 | 2018-05-30 | トランジェーヌ、ソシエテ、アノニムTransgene S.A. | マイコバクテリア抗原ワクチン |
WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
WO2014078688A2 (en) | 2012-11-16 | 2014-05-22 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and use thereof |
KR102089121B1 (ko) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양살상형 아데노바이러스 조성물 |
MX361774B (es) | 2013-04-25 | 2018-12-17 | Janssen Vaccines & Prevention Bv | Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados. |
PE20160045A1 (es) | 2013-06-17 | 2016-02-18 | Crucell Holland Bv | Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados |
AU2014338864C1 (en) | 2013-10-25 | 2020-07-16 | Akamis Bio Limited | Oncolytic adenoviruses armed with heterologous genes |
JP6605480B2 (ja) | 2014-01-09 | 2019-11-13 | トランスジェン・ソシエテ・アノニム | ヘテロオリゴマーマイコバクテリア抗原の融合物 |
HRP20240163T1 (hr) | 2014-09-03 | 2024-04-12 | Bavarian Nordic A/S | Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom |
MX2017002890A (es) | 2014-09-03 | 2017-11-13 | Bavarian Nordic As | Métodos y composiciones para potenciar respuestas inmunitarias. |
PT3197489T (pt) | 2014-09-26 | 2021-04-30 | Beth Israel Deaconess Medical Ct Inc | Métodos e composições para induzir a imunidade protetora contra a infeção pelo vírus da imunodeficiência humana |
CN107075521B (zh) | 2014-11-04 | 2021-06-08 | 扬森疫苗与预防公司 | 治疗性hpv16疫苗 |
US10570417B2 (en) | 2015-04-14 | 2020-02-25 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
IL284375B (en) | 2015-04-30 | 2022-07-01 | Psioxus Therapeutics Ltd | A replication-competent group b oncolytic adenovirus |
JP6840718B2 (ja) | 2015-07-07 | 2021-03-10 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定化された可溶性融合前rsv fポリペプチド |
WO2017005844A1 (en) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
EA037295B1 (ru) | 2015-08-20 | 2021-03-05 | Янссен Вэксинс Энд Превеншн Б.В. | Терапевтические вакцины против hpv18 |
CN108368157B (zh) | 2015-12-15 | 2022-04-15 | 扬森疫苗与预防公司 | 人类免疫缺陷病毒抗原、载体、组合物、及其使用方法 |
BR112018012180A2 (pt) | 2015-12-17 | 2018-12-04 | Psioxus Therapeutics Ltd | vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr |
CN117384961A (zh) | 2016-02-23 | 2024-01-12 | 萨克生物研究学院 | 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达 |
EP3390428B1 (en) | 2016-02-23 | 2019-09-25 | Salk Institute for Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
AU2017248021B2 (en) | 2016-04-05 | 2021-08-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
BR112018070323A2 (pt) | 2016-04-05 | 2019-01-29 | Janssen Vaccines & Prevention Bv | vacina contra rsv |
AU2017259259B2 (en) | 2016-05-02 | 2020-11-19 | Bavarian Nordic A/S | Therapeutic HPV vaccine combinations |
WO2017207480A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
JP6595132B2 (ja) | 2016-06-16 | 2019-10-23 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Hivワクチン製剤 |
US11001858B2 (en) | 2016-06-20 | 2021-05-11 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
WO2018011196A1 (en) | 2016-07-14 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
WO2018011768A1 (en) | 2016-07-15 | 2018-01-18 | Janssen Vaccines And Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
WO2018011198A1 (en) | 2016-07-15 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
CN110062630A (zh) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | 肿瘤靶向合成腺病毒及其用途 |
KR102111244B1 (ko) | 2017-02-09 | 2020-05-15 | 얀센 백신스 앤드 프리벤션 비.브이. | 이종 유전자의 발현을 위한 강력한 짧은 프로모터 |
WO2018185732A1 (en) | 2017-04-06 | 2018-10-11 | Janssen Vaccines & Prevention B.V. | Mva-bn and ad26.zebov or ad26.filo prime-boost regimen |
WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
EP3624844A1 (en) | 2017-05-17 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
JP7272965B2 (ja) | 2017-06-15 | 2023-05-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Hiv抗原をコードするポックスウイルスベクターおよびその使用方法 |
EP3681533A1 (en) | 2017-09-15 | 2020-07-22 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against rsv |
EP3713599A1 (en) | 2017-11-20 | 2020-09-30 | Janssen Pharmaceuticals, Inc. | Method of providing safe administration of adenoviral vectors encoding a zika virus antigen |
WO2019118480A1 (en) | 2017-12-11 | 2019-06-20 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and uses thereof |
KR20200100745A (ko) | 2017-12-19 | 2020-08-26 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물 |
BR112021000274A2 (pt) | 2018-07-20 | 2021-04-06 | Janssen Vaccines & Prevention B.V. | Vetor adenoviral recombinante expressando antígeno de zika com produtividade melhorada |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | ***新抗原及其用途 |
CA3140234A1 (en) | 2019-05-15 | 2020-11-19 | Janssen Vaccines & Prevention B.V. | Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine |
US20220273787A1 (en) | 2019-05-15 | 2022-09-01 | Janssen Vaccines & Prevention B.V. | Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine |
AU2020385683A1 (en) | 2019-11-18 | 2022-06-30 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
CN111337042B (zh) * | 2020-03-13 | 2021-11-02 | 湖北大学 | 一种车辆路径规划方法及*** |
JP2023521194A (ja) | 2020-04-13 | 2023-05-23 | ヤンセン バイオテツク,インコーポレーテツド | Psma及びsteap1ワクチン並びにそれらの使用 |
US20230024133A1 (en) | 2020-07-06 | 2023-01-26 | Janssen Biotech, Inc. | Prostate Neoantigens And Their Uses |
US20230035403A1 (en) | 2020-07-06 | 2023-02-02 | Janssen Biotech, Inc. | Method For Determining Responsiveness To Prostate Cancer Treatment |
EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
WO2022008613A1 (en) | 2020-07-08 | 2022-01-13 | Janssen Sciences Ireland Unlimited Company | Rna replicon vaccines against hbv |
GB202013940D0 (en) | 2020-09-04 | 2020-10-21 | Synpromics Ltd | Regulatory nucleic acid sequences |
EP4225382A2 (en) | 2020-10-07 | 2023-08-16 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 |
WO2022140759A2 (en) | 2020-12-23 | 2022-06-30 | Janssen Biotech, Inc. | Neoantigen peptide mimics |
WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2725726B1 (fr) * | 1994-10-17 | 1997-01-03 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en therapie genique |
US5856152A (en) * | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
ES2333425T5 (es) | 1995-06-15 | 2012-08-28 | Crucell Holland B.V. | Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica |
US5837511A (en) * | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
US5877011A (en) * | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
US6100086A (en) * | 1997-04-14 | 2000-08-08 | Genzyme Corporation | Transgene expression systems |
WO2000052186A1 (en) * | 1999-03-04 | 2000-09-08 | Introgene B.V. | Means and methods for fibroblast-like or macrophage-like cell transduction |
AU2009254168A1 (en) * | 2008-06-03 | 2009-12-10 | Okairos Ag | A vaccine for the prevention and therapy of HCV infections |
-
2000
- 2000-05-16 EP EP07106054A patent/EP1816205B1/en not_active Expired - Lifetime
- 2000-05-16 PT PT07106054T patent/PT1816205E/pt unknown
- 2000-05-16 EP EP07106036A patent/EP1818408B1/en not_active Expired - Lifetime
- 2000-05-16 KR KR1020017014631A patent/KR100741247B1/ko active IP Right Grant
- 2000-05-16 EP EP05077719A patent/EP1681353B1/en not_active Expired - Lifetime
- 2000-05-16 AU AU49547/00A patent/AU777041B2/en not_active Expired
- 2000-05-16 CA CA2372655A patent/CA2372655C/en not_active Expired - Lifetime
- 2000-05-16 PT PT07106036T patent/PT1818408E/pt unknown
- 2000-05-16 DK DK05077719T patent/DK1681353T3/da active
- 2000-05-16 WO PCT/NL2000/000325 patent/WO2000070071A1/en active Application Filing
- 2000-05-16 ES ES07106054T patent/ES2372824T3/es not_active Expired - Lifetime
- 2000-05-16 EP EP04077434A patent/EP1550722B1/en not_active Expired - Lifetime
- 2000-05-16 JP JP2000618477A patent/JP4843145B2/ja not_active Expired - Lifetime
- 2000-05-16 EP EP07106044A patent/EP1816204B1/en not_active Expired - Lifetime
- 2000-05-16 AT AT04077434T patent/ATE364707T1/de active
- 2000-05-16 DE DE60045138T patent/DE60045138D1/de not_active Expired - Lifetime
- 2000-05-16 DK DK00201738.2T patent/DK1054064T4/da active
- 2000-05-16 ES ES07106044T patent/ES2354578T3/es not_active Expired - Lifetime
- 2000-05-16 AT AT07106036T patent/ATE519855T1/de active
- 2000-05-16 EP EP00201738A patent/EP1054064B2/en not_active Expired - Lifetime
- 2000-05-16 DE DE60035229T patent/DE60035229T2/de not_active Expired - Lifetime
- 2000-05-16 DE DE60014489T patent/DE60014489T3/de not_active Expired - Lifetime
- 2000-05-16 PT PT07106044T patent/PT1816204E/pt unknown
- 2000-05-16 PT PT00201738T patent/PT1054064E/pt unknown
- 2000-05-16 AT AT00201738T patent/ATE278792T1/de active
- 2000-05-16 DK DK07106044.6T patent/DK1816204T3/da active
- 2000-05-16 DE DE60043126T patent/DE60043126D1/de not_active Expired - Lifetime
- 2000-05-16 ES ES07106036T patent/ES2372823T3/es not_active Expired - Lifetime
- 2000-05-16 AT AT07106044T patent/ATE485382T1/de active
- 2000-05-16 ES ES04077434T patent/ES2289426T3/es not_active Expired - Lifetime
- 2000-05-16 IL IL14647988A patent/IL146479A0/xx unknown
- 2000-05-16 NZ NZ515582A patent/NZ515582A/en not_active IP Right Cessation
- 2000-05-16 PT PT04077434T patent/PT1550722E/pt unknown
- 2000-05-16 AT AT07106054T patent/ATE519854T1/de active
- 2000-05-16 AT AT05077719T patent/ATE445018T1/de not_active IP Right Cessation
- 2000-05-16 DK DK04077434T patent/DK1550722T3/da active
- 2000-05-16 ES ES00201738T patent/ES2231103T5/es not_active Expired - Lifetime
- 2000-05-16 DK DK07106054.5T patent/DK1816205T3/da active
- 2000-05-16 DK DK07106036.2T patent/DK1818408T3/da active
-
2001
- 2001-11-13 IL IL146479A patent/IL146479A/en not_active IP Right Cessation
-
2007
- 2007-07-25 CY CY20071100996T patent/CY1106762T1/el unknown
-
2011
- 2011-01-10 CY CY20111100030T patent/CY1111494T1/el unknown
- 2011-07-14 JP JP2011156125A patent/JP5335037B2/ja not_active Expired - Lifetime
- 2011-08-02 IL IL214413A patent/IL214413A/en not_active IP Right Cessation
- 2011-11-07 CY CY20111101075T patent/CY1112189T1/el unknown
- 2011-11-07 CY CY20111101074T patent/CY1112008T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1681353T3 (da) | Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35 | |
EE05538B1 (et) | Interleukiin-18 seostuvad valgud, nende valmistamine ja kasutamine | |
ATE237694T1 (de) | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt | |
EP1522588A3 (en) | Accessory functions for use in recombinant AAV virion production | |
NZ336829A (en) | Adenoviruses having altered hexon proteins which present epitopes that are not recognised by neutralizing antibodies to the unmodified adenovirus of another serotype | |
WO2000073478A3 (en) | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration | |
WO2002018948A3 (en) | Differentially expressed epitopes and uses thereof | |
JP2002537816A5 (da) | ||
EP1270586A3 (de) | Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen | |
AU2002228805A1 (en) | Antisense modulation of damage-specific dna binding protein 2, p48 expression | |
NO20020367D0 (no) | Konjugater og fremgangsmåter for fremstilling derav, og deres anvendelse for transportering av molekyler via biologiskemembraner | |
WO2006086357A3 (en) | Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby | |
WO2002083896A3 (en) | Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same | |
AU6679498A (en) | A novel bak binding protein, dna encoding the protein, and methods of use thereof | |
WO2002083902A3 (en) | Adenovirus serotype 30 (ad30) fiber protein and uses thereof | |
WO2001081607A3 (en) | Adenovirus vectors with knobless fibers, and their uses | |
坂口実 | TWO-PERSON HI-LO POKER: STUD AND DRAW, II | |
AU3359197A (en) | Game medium and banknote transfer system using air stream | |
AU2000265672A1 (en) | Somatic cloning gene transfer for the production of recombinant proteins, cells and organs | |
Mohlenbrock | Leaf Reading in Oahu. | |
ZA987310B (en) | Interleukin-18 binding proteins, their preparation and use. | |
AU2003200442A1 (en) | Interleukin-18 binding proteins, their preparation and use |